JP2008500363A - 新規化合物、該化合物を含む医薬組成物、および該化合物の使用方法 - Google Patents

新規化合物、該化合物を含む医薬組成物、および該化合物の使用方法 Download PDF

Info

Publication number
JP2008500363A
JP2008500363A JP2007515318A JP2007515318A JP2008500363A JP 2008500363 A JP2008500363 A JP 2008500363A JP 2007515318 A JP2007515318 A JP 2007515318A JP 2007515318 A JP2007515318 A JP 2007515318A JP 2008500363 A JP2008500363 A JP 2008500363A
Authority
JP
Japan
Prior art keywords
compound
pharmaceutical composition
alkyl
fas
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007515318A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500363A5 (cg-RX-API-DMAC7.html
Inventor
ジル・エム・スターディバント
クレイグ・エイ・タウンゼント
スーザン・エム・メドゴールチ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fasgen LLC
Original Assignee
Fasgen LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fasgen LLC filed Critical Fasgen LLC
Publication of JP2008500363A publication Critical patent/JP2008500363A/ja
Publication of JP2008500363A5 publication Critical patent/JP2008500363A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/02—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms
    • A01N43/04—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom
    • A01N43/06—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atoms with one hetero atom five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
JP2007515318A 2004-05-26 2005-05-25 新規化合物、該化合物を含む医薬組成物、および該化合物の使用方法 Pending JP2008500363A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57463904P 2004-05-26 2004-05-26
PCT/US2005/018443 WO2005117590A2 (en) 2004-05-26 2005-05-25 Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Publications (2)

Publication Number Publication Date
JP2008500363A true JP2008500363A (ja) 2008-01-10
JP2008500363A5 JP2008500363A5 (cg-RX-API-DMAC7.html) 2008-07-17

Family

ID=35463277

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007515318A Pending JP2008500363A (ja) 2004-05-26 2005-05-25 新規化合物、該化合物を含む医薬組成物、および該化合物の使用方法

Country Status (13)

Country Link
US (1) US20090005435A1 (cg-RX-API-DMAC7.html)
EP (1) EP1758577A4 (cg-RX-API-DMAC7.html)
JP (1) JP2008500363A (cg-RX-API-DMAC7.html)
KR (1) KR20070095754A (cg-RX-API-DMAC7.html)
CN (1) CN101022792A (cg-RX-API-DMAC7.html)
AU (1) AU2005249437A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510397A (cg-RX-API-DMAC7.html)
CA (1) CA2568639A1 (cg-RX-API-DMAC7.html)
IL (1) IL179530A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06013687A (cg-RX-API-DMAC7.html)
RU (1) RU2006146051A (cg-RX-API-DMAC7.html)
WO (1) WO2005117590A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200700024B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014248A2 (en) * 2005-07-26 2007-02-01 Johns Hopkins University Method of reducing food intake
AU2007300627B2 (en) * 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
KR101640263B1 (ko) * 2007-10-05 2016-07-15 젠자임 코포레이션 세라마이드 유도체로 다낭성 신장질환을 치료하는 방법
WO2010118324A2 (en) 2009-04-09 2010-10-14 Nuclea Biotechnologies, LLC Antibodies against fatty acid synthase
WO2014039769A1 (en) * 2012-09-07 2014-03-13 Janssen Pharmaceutica Nv Imidazolin-5-one derivatives useful as fatty acid snthase (fasn) inhibitors for|the treatment of cancer
CA2968288A1 (en) 2014-11-20 2016-05-26 Vib Vzw Means and methods for treatment of early-onset parkinson's disease
CN114980740A (zh) 2020-01-23 2022-08-30 巴斯夫欧洲公司 用于农业化学配制剂的新型添加剂
CN116507203B (zh) 2020-10-27 2026-08-07 巴斯夫欧洲公司 农药微乳剂组合物
CA3207197A1 (en) 2021-02-05 2022-08-11 Murat Mertoglu Liquid herbicidal compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005277A1 (en) * 2002-07-09 2004-01-15 Fasgen, Inc. Novel compunds, pharmaceutical compositions containing same, and methods of use for same
JP2005523270A (ja) * 2002-02-08 2005-08-04 ジョーンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン 体重を減少させる方法としてのcpt−1の促進

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3427847A1 (de) * 1983-12-09 1985-06-13 Bayer Ag, 5090 Leverkusen Thiolan-2,4-dion-3-carboxamide
US5759837A (en) * 1989-01-17 1998-06-02 John Hopkins University Chemotherapy for cancer by inhibiting the fatty acid biosynthetic pathway
US5614551A (en) * 1994-01-24 1997-03-25 The Johns Hopkins University Inhibitors of fatty acid synthesis as antimicrobial agents
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523270A (ja) * 2002-02-08 2005-08-04 ジョーンズ・ホプキンス・ユニバーシティ・スクール・オブ・メディシン 体重を減少させる方法としてのcpt−1の促進
WO2004005277A1 (en) * 2002-07-09 2004-01-15 Fasgen, Inc. Novel compunds, pharmaceutical compositions containing same, and methods of use for same

Also Published As

Publication number Publication date
WO2005117590A3 (en) 2006-07-27
WO2005117590A2 (en) 2005-12-15
ZA200700024B (en) 2008-06-25
AU2005249437A1 (en) 2005-12-15
RU2006146051A (ru) 2008-07-10
EP1758577A2 (en) 2007-03-07
BRPI0510397A (pt) 2007-11-13
US20090005435A1 (en) 2009-01-01
EP1758577A4 (en) 2010-05-05
CA2568639A1 (en) 2005-12-15
IL179530A0 (en) 2007-05-15
MXPA06013687A (es) 2007-10-18
CN101022792A (zh) 2007-08-22
KR20070095754A (ko) 2007-10-01

Similar Documents

Publication Publication Date Title
US7649012B2 (en) Compounds, pharmaceutical compositions containing same, and methods of use for same
CN100482219C (zh) 新化合物、包含该化合物的药物组合物及该化合物的应用方法
AU703272B2 (en) Inhibitors of fatty acid synthesis as antimicrobial agents
US20090005435A1 (en) Novel Compounds, Pharmaceutical Compositions Containing Same, and Methods of Use for Same
US20100168176A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20100029752A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
US20100029761A1 (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HK1112837A (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same
HK1086485B (en) Novel compounds, pharmaceutical compositions containing same, and methods of use for same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110823

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120131